Gladius Pharmaceuticals is developing a novel, once-daily siderophore antibiotic for the treatment of multi-drug resistant pseudomonas aeruginosa and other prevalent Gram-negative bacteria.
Employees: 11-50
Investors 1
| Date | Name | Website |
| - | Lumira Ven... | lumiravent... |
Mentions in press and media 1
| Date | Title | Description |
| 22.06.2015 | Gladius Pharmaceuticals raises CAD $4.1 million to battle multi-drug-resistant infections | MONTRÉAL, Gladius Pharmaceuticals Inc., a Montréal-based biotechnology firm developing novel drugs to treat life-threatening, multi-drug-resistant bacterial infections, announced today the closing of a $4.1 million Series A financing. The r... |